Business
Stoke Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
– Enrollment and dosing ongoing in the Phase 1/2a MONARCH and ADMIRAL studies of STK-001 in children and adolescents with Dravet syndrome – – Company remains
About this update from Stoke Therapeutics, Inc.
[{"type":"text","content":"\n– Enrollment and dosing ongoing in the Phase 1/2a MONARCH and ADMIRAL studies of STK-001 in children and adolescents with Dravet syndrome –\n\n– Company remains on track to provide additional clinical data in 2H 2022 from patients treated with multiple ascending doses of STK-001 at 30mg –\n\n– Preclinical toxicology studies underway for STK-002, the first potential disease-modifying approach for the treatment of Autosomal Dominant Optic Atrophy (ADOA) –\n\n– As of December 31, 2021, Company had $220.4 million in cash, cash equivalents, marketable securities, and restricted cash –\n\n BEDFORD, Mass.--(BUSINESS WIRE)--\nStoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the full year ended December 31, 2021 and provided business updates.\n\n“During the past year, the Stoke team made significant progress with STK-001 in the clinic and advanced our pipeline of potential medicines for diseases of the central nervous system and the eye,” said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics. “In December 2021, we shared positive interim data for STK-001 in children and adolescents with Dravet syndrome and today we are announcing continued clinical momentum with dosing of patients at 45mg in our MONARCH and ADMIRAL studies. Our ADOA program is progressing nicely with the nomination of STK-002 as a clinical candidate and the recent start of preclinical toxicology studies to support potential future clinical trials. Our recent collaboration with Acadia Pharmaceuticals unlocks three pipeline targets focused on severe and rare neurodevelopmental diseases and brings additional resources to help us expand the potential of TANGO to additional patient populations. With the fundamentals in place, including a strong financial position, we believe we are well-positioned to continue to execute on our goals for 2022.”\n\nFourth Quarter 2021 Business Highlights and Recent Developments\n\n\nToday, the Company announced continued clinical progress in the Phase 1/2a studies. The first patients have been dosed with STK-001 at 45mg in the single ascending dose portion of the MONARCH study. The first patients have also been dosed with STK-001 at 45mg in the ADMI...